Photo/Liu Xuemei (NBD)

NO.1 Sam Altman Returns to OpenAI Board

On March 8, 2023, OpenAI, a leading global artificial intelligence startup, announced that its CEO Sam Altman will rejoin the non-profit board that oversees the company. In a press release published on its website, OpenAI said that the law firm WilmerHale's investigation into Altman's dismissal in November 2022 has concluded, and the company has developed new governance rules and strengthened its conflict-of-interest policies. The board said it unanimously supports Altman's leadership.

Commentary: Altman's return could bring stability to OpenAI, strengthen corporate governance, and help maintain its leading position in the AI field.

NO.2 Novo Nordisk's Wegovy Approved by FDA for Cardiovascular Disease

On March 8, 2023, the U.S. Food and Drug Administration (FDA) approved the blockbuster weight loss drug Wegovy to reduce the risk of stroke and heart attack in overweight or obese adults. As a new weight loss drug from Novo Nordisk, Wegovy and the company's diabetes drug Ozempic contain the same active ingredient, semaglutide, which was originally designed to treat type 2 diabetes. It belongs to a class of drugs called GLP-1 (glucagon-like peptide-1).

Commentary: The FDA's approval could boost Wegovy's market competitiveness, which is also a big positive for Novo Nordisk in the capital market.

NO.3 FDA Delays Approval of Lilly's New Alzheimer's Drug

On March 8, 2023, U.S. pharmaceutical giant Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has unexpectedly delayed its approval decision on its new Alzheimer's drug Donanemab and will convene an external expert panel to discuss the drug's safety and efficacy. Lilly said the date of the FDA advisory committee meeting to discuss Donanemab has not been set but could take several months, so approval is expected to be delayed beyond the first quarter.

Commentary: The FDA's decision could mean that Lilly will need to invest more time in research and preparation to ensure the safety and efficacy of the new drug.

NO.4 Apple Plans to Launch Foldable iPhone in 2026

According to media reports, the U.S. Patent and Trademark Office has published a patent application from Apple, showcasing the design of Apple's future foldable products, including a variety of products such as iPhones, hybrid tablet laptops, and more. In response to the patent, Apple executives said: "After careful consideration, the company has confirmed that it will delay the release of its first foldable iPhone until 2026, which is later than expected internally."

Commentary: Apple's delay in releasing the foldable iPhone shows that the company values product quality.

NO.5 Microsoft Launches Custom GPT Feature for Copilot Pro Users

According to foreign media, Microsoft Bing Vice President Michael Schechter said that Microsoft has begun to roll out the Copilot GPT Builder feature to Copilot Pro users, allowing users to create their own custom GPT features. Microsoft said that these custom GPTs will support customization for areas such as travel, cooking, and fitness, and free users can also use them freely.

Commentary: Microsoft provides Copilot Pro users with a more personalized service experience, which helps to improve user satisfaction and product competitiveness.

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using.